Journal of Interventional Medicine最新文献

{"title":"Baseline parameters of spectral CT could predict tumor response to transcatheter arterial chemoembolization in hepatocellular carcinoma patients","authors":"Jian Lv, Ronghua Mu, Xiaoyan Qin, Wei Zheng, Peng Yang, Bingqin Huang, Xin Li, Fuzhen Liu, Xiqi Zhu","doi":"10.1016/j.jimed.2023.12.005","DOIUrl":"https://doi.org/10.1016/j.jimed.2023.12.005","url":null,"abstract":"","PeriodicalId":33533,"journal":{"name":"Journal of Interventional Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139393806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Percutaneous radiofrequency and microwave ablation for renal pelvic urothelial carcinoma with refractory hematuria: A case report","authors":"Wei-Guo Tang, Yu Wu, Juan-Juan Xu, Xi Li, Yuan Liu","doi":"10.1016/j.jimed.2023.12.006","DOIUrl":"https://doi.org/10.1016/j.jimed.2023.12.006","url":null,"abstract":"","PeriodicalId":33533,"journal":{"name":"Journal of Interventional Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139637519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic radiology: The essential for effective and safe practice of interventional radiology","authors":"Xiaoming Yang","doi":"10.1016/j.jimed.2023.12.001","DOIUrl":"https://doi.org/10.1016/j.jimed.2023.12.001","url":null,"abstract":"","PeriodicalId":33533,"journal":{"name":"Journal of Interventional Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139539423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chinese expert consensus on transradial access in percutaneous peripheral interventions","authors":"Minjie Yang ,&nbsp;Sen Jiang ,&nbsp;Yanli Wang ,&nbsp;Xiaoxi Meng ,&nbsp;Liwen Guo ,&nbsp;Wen Zhang ,&nbsp;Xin Zhou ,&nbsp;Zhiping Yan ,&nbsp;Jiarui Li ,&nbsp;Weihua Dong","doi":"10.1016/j.jimed.2023.10.005","DOIUrl":"10.1016/j.jimed.2023.10.005","url":null,"abstract":"<div><p>Transradial access (TRA) is a safe and comfortable approach and the preferred access for percutaneous coronary intervention. However, TRA is not widely used for peripheral interventions. Currently, there is a lack of data on patient selection, appropriate medical devices, complication prevention, and TRA adoption. Therefore, the Chinese Society of Interventional Oncology of the China Anti-Cancer Association organized nationwide experts to establish a Working Group of China Expert Consensus on TRA in percutaneous peripheral interventions in 2022, and jointly formulated this consensus to better promote the application of TRA in peripheral interventions to guide clinicians on patient selection, technical recommendations, and physician training. This consensus mainly focuses on the current situation, advantages and limitations of TRA in peripheral interventions, anatomical characteristics of the radial artery, patient selection, technical aspects, prevention and management of complications, radiation dose, and learning curve. A consensus was reached through a literature evaluation and by referring to the opinions of the expert group.</p></div>","PeriodicalId":33533,"journal":{"name":"Journal of Interventional Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2096360223000546/pdfft?md5=2beb81511b4f2f0f1378f9f6e7ae60b4&pid=1-s2.0-S2096360223000546-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135610058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel cerebrovascular drug-coated balloon catheter for treating symptomatic intracranial atherosclerotic stenosis lesions: Study protocol for a prospective, multicenter, single-arm, target-value clinical trial","authors":"Qianhao Ding ,&nbsp;Wenbo Liu ,&nbsp;Jingge Zhao ,&nbsp;Dehua Guo ,&nbsp;Yao Tang ,&nbsp;Tengfei Zhou ,&nbsp;Yanyan He ,&nbsp;Ferdinand K. Hui ,&nbsp;Yonghong Ding ,&nbsp;Liangfu Zhu ,&nbsp;Zilang Wang ,&nbsp;Yingkun He ,&nbsp;Tianxiao Li","doi":"10.1016/j.jimed.2023.10.001","DOIUrl":"10.1016/j.jimed.2023.10.001","url":null,"abstract":"<div><h3>Background</h3><p>Previous single-center studies have demonstrated that drug-coated balloons (DCBs) may reduce restenosis rates, which is an important factor affecting the prognosis for intracranial interventional therapy. However, currently available cardiac DCBs are not always suitable for the treatment of intracranial atherosclerotic stenosis (ICAS). This study aimed to evaluate the safety and efficacy of a novel DCB catheter designed for patients with severely symptomatic ICAS.</p></div><div><h3>Methods</h3><p>This prospective, multicenter, single-arm, target-value clinical trial was conducted in 9 Chinese stroke centers to evaluate the safety and efficacy of a novel DCB catheter for treating symptomatic severe ICAS. Primary metrics and other indicators were collected and analyzed using SAS version 9.4 (SAS Institute, Cary, NC, USA).</p></div><div><h3>Results</h3><p>A total of 155 patients were enrolled in this study. The preliminary collection of follow-up data has been completed, while data quality control is ongoing.</p></div><div><h3>Conclusion</h3><p>Results of this study demonstrated the patency rate, safety, and effectiveness of a novel on-label paclitaxel DCB designed for the treatment of ICAS.</p></div><div><h3>Trial registration</h3><p>ChiCTR, ChiCTR2100047223. Registered June 11, 2021-Prospective registration, <span>https://www.chictr.org.cn/ChiCTR2100047223</span><svg><path></path></svg>.</p></div>","PeriodicalId":33533,"journal":{"name":"Journal of Interventional Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2096360223000509/pdfft?md5=006fb83c21cb784f33f998c779d04aa7&pid=1-s2.0-S2096360223000509-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136094051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Argon-helium cryoablation treatment of undifferentiated pleomorphic sarcoma of the thyroid: A case report and literature review","authors":"Xuyang Zhang,&nbsp;Yan Sun","doi":"10.1016/j.jimed.2023.10.002","DOIUrl":"10.1016/j.jimed.2023.10.002","url":null,"abstract":"<div><p>Undifferentiated pleomorphic sarcoma is an extremely rare malignant thyroid tumor. Thyroid sarcoma differs from common malignant thyroid tumors, such as thyroid follicular cell carcinoma. It is usually highly malignant, progresses rapidly, and is prone to remote metastasis. Currently, there is no standard protocol for the treatment of thyroid sarcomas, and most treatment effects are unsatisfactory. Argon-helium cryoablation is an important method of local treatment that is widely used in patients with unresectable advanced tumors. However, owing to the low incidence of thyroid sarcomas, there are no relevant literature reports on the treatment of thyroid sarcomas using cryoablation in China. This study reports the case of a patient with undifferentiated pleomorphic sarcoma of the thyroid gland who was treated with argon-helium cryoablation, and the immediate outcome was good. Based on a review of relevant literature, we discussed the effectiveness and safety of argon-helium cryoablation treatment to provide clinical guidance and references for the treatment of patients with thyroid sarcoma.</p></div>","PeriodicalId":33533,"journal":{"name":"Journal of Interventional Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2096360223000510/pdfft?md5=a7e4fd5f11a56b593e473849d3147e95&pid=1-s2.0-S2096360223000510-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136009493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combination of transarterial radioembolization with atezolizumab and bevacizumab for intermediate and advanced staged hepatocellular carcinoma: A preliminary report of safety and feasibility","authors":"Qian Yu ,&nbsp;Yating Wang ,&nbsp;Ethan Ungchusri ,&nbsp;Mikin Patel ,&nbsp;Divya Kumari ,&nbsp;Thuong Van Ha ,&nbsp;Anjana Pillai ,&nbsp;Chih-yi Liao ,&nbsp;Osman Ahmed","doi":"10.1016/j.jimed.2023.09.002","DOIUrl":"10.1016/j.jimed.2023.09.002","url":null,"abstract":"<div><h3>Purpose</h3><p>The IMbrave150 Phase III trial demonstrated the superiority of atezolizumab and bevacizumab (Atezo/Bev) over sorafenib for unresectable hepatocellular carcinoma (HCC). The present study aims to evaluate the feasibility of TARE in combination with Atezo/Bev for the treatment of intermediate and advanced staged HCC.</p></div><div><h3>Methods</h3><p>A retrospective review at a single institution was performed between May 2021 and December 2022. Patients who received TARE using yttrium-90 (Y90) with concomitant or sequential Atezo/Bev systemic treatment were included. The following outcomes were retrieved: overall survival (OS), radiologic tumor response, progression-free survival, technical adverse events related to TARE, and toxicity based on the National Cancer Institute–Common Terminology Criteria for Adverse Events version 5.0.</p></div><div><h3>Results</h3><p>Ten consecutive patients with intermediate (n ​= ​4) and advanced stage HCC (n ​= ​6) were treated with TARE and sequential/concomitant Atezo/Bev. Tumor control was achieved in all TARE-treated target lesions (100%). Overall disease progression occurred in 4 patients with PFS of 78.8% and 66.7% at 6- and 12- months, respectively. Two patients died at follow-up, with 6-month and 12-month OS rates of 90.0% and 77.1%, respectively. Three (75%) patients with intermediate stage disease were downstaged into Milan criteria. One patient developed grade 3 transaminitis and hypoglobulinemia, while Atezo/Bev was switched to Lenvatinib in another patient due to immunotherapy related myositis.</p></div><div><h3>Conclusion</h3><p>This study demonstrates the initial safety and feasibility of combined TARE with Atezo/Bev for intermediate/advanced stage HCC. Further prospective studies with larger sample sizes are warranted.</p></div>","PeriodicalId":33533,"journal":{"name":"Journal of Interventional Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2096360223000480/pdfft?md5=d5a608b1799dc3158654f8d07ef0110c&pid=1-s2.0-S2096360223000480-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134994586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current status of yttrium-90 microspheres radioembolization in primary and metastatic liver cancer","authors":"Yasaman Anbari ,&nbsp;Floortje E. Veerman ,&nbsp;Grace Keane ,&nbsp;Arthur J.A.T. Braat ,&nbsp;Maarten L.J. Smits ,&nbsp;Rutger C.G. Bruijnen ,&nbsp;Wenle Tan ,&nbsp;Ye Li ,&nbsp;Feng Duan ,&nbsp;Marnix G.E.H. Lam","doi":"10.1016/j.jimed.2023.09.001","DOIUrl":"10.1016/j.jimed.2023.09.001","url":null,"abstract":"<div><p>Liver malignancy, including primary liver cancer and metastatic liver cancer, has become one of the most common causes of cancer-related death worldwide due to the high malignant degree and limited systematic treatment strategy. Radioembolization with yttrium-90 (⁹⁰Y)-loaded microspheres is a relatively novel technology that has made significant progress in the local treatment of liver malignancy. The different steps in the extensive work-up of radioembolization for patients with an indication for treatment with ⁹⁰Y microspheres, from patient selection to follow up, both technically and clinically, are discussed in this paper. It describes the application and development of ⁹⁰Y microspheres in the treatment of liver cancer.</p></div>","PeriodicalId":33533,"journal":{"name":"Journal of Interventional Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2096360223000479/pdfft?md5=5035fae5d67492f85a90cced74213303&pid=1-s2.0-S2096360223000479-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135388710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanisms and therapeutic strategies to combat the recurrence and progression of hepatocellular carcinoma after thermal ablation","authors":"Feilong Ye ,&nbsp;Lulu Xie ,&nbsp;Licong Liang ,&nbsp;Zhimei Zhou,&nbsp;Siqin He,&nbsp;Rui Li,&nbsp;Liteng Lin,&nbsp;Kangshun Zhu","doi":"10.1016/j.jimed.2023.10.004","DOIUrl":"10.1016/j.jimed.2023.10.004","url":null,"abstract":"<div><p>Thermal ablation (TA), including radiofrequency ablation (RFA) and microwave ablation (MWA), has become the main treatment for early-stage hepatocellular carcinoma (HCC) due to advantages such as safety and minimal invasiveness. However, HCC is prone to local recurrence, with more aggressive malignancies after TA closely related to TA-induced changes in epithelial-mesenchymal transition (EMT) and remodeling of the tumor microenvironment (TME). According to many studies, various components of the TME undergo complex changes after TA, such as the recruitment of innate and adaptive immune cells, the release of tumor-associated antigens (TAAs) and various cytokines, the formation of a hypoxic microenvironment, and tumor angiogenesis. Changes in the TME after TA can partly enhance the anti-tumor immune response; however, this response is weak to kill the tumor completely. Certain components of the TME can induce an immunosuppressive microenvironment through complex interactions, leading to tumor recurrence and progression. How the TME is remodeled after TA and the mechanism by which the TME promotes HCC recurrence and progression are unclear. Thus, in this review, we focused on these issues to highlight potentially effective strategies for reducing and preventing the recurrence and progression of HCC after TA.</p></div>","PeriodicalId":33533,"journal":{"name":"Journal of Interventional Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2096360223000534/pdfft?md5=07a052f542e22188d7d974bf898ef593&pid=1-s2.0-S2096360223000534-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135849720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Embolization of brain arteriovenous malformations with squid co-polymer embolic material: Initial experience","authors":"Li Shyan Ch'ng ,&nbsp;Zulkifli Zaki ,&nbsp;Ahmad Sobri Muda","doi":"10.1016/j.jimed.2023.09.003","DOIUrl":"10.1016/j.jimed.2023.09.003","url":null,"abstract":"<div><h3>Objective</h3><p>To analyze the safety and effectiveness of the ethylene-vinyl alcohol copolymer (EVOH) liquid embolic agent Squid (Emboflu, Switzerland) for the treatment of brain arteriovenous malformations.</p></div><div><h3>Materials and procedures</h3><p>Between April 2015 and July 2017, 46 embolization treatments for brain arteriovenous malformations (BAVM) were performed in 25 patients using two Squid formulations (18 and 12). Six female and 19 male patients with a mean age of 34 years (range, 9–62 years) were included. A total of 46 procedures were performed. The BAVMs were classified as Spetzler-Martin grade II in 4 procedures, III in 27 procedures, and 1V in 15 procedures. Among the 25 patients, 15 presented with hemorrhage, 5 with seizures, and 5 with headache and neurology. The BAVMs were located in the temporal lobe in 5 patients, parietal lobe in 7 patients, frontal lobe in 3 patients, posterior fossa in 6 patients, basal ganglia in 3 patients, and parasagittal lobe in 1 patient.</p></div><div><h3>Results</h3><p>The obliteration rate of the BAVMs ranged from 10% to 100%, with a mean of 33%. Most patients underwent their first or second embolization procedure. Four patients (8%) developed intracranial bleeding post-procedure, with one death (2%). One patient (2%) experienced a seizure during the procedure; however, no intracranial bleeding was observed. Seven patients (15%) experienced perforations during catheter manipulation. One case (2%) of a fractured catheter was recorded, but no significant complications were observed. The average volume of copolymer injected was 0.6 ​ml per nidus. Thirteen procedures used the Squid-12 formulation, 29 procedures used the Squid-18 formulation, and 3 procedures used a combination of Squid-12 and -18 formulations.</p></div><div><h3>Conclusion</h3><p>Squid is a safe and effective embolic agent for treating BAVMs.</p></div>","PeriodicalId":33533,"journal":{"name":"Journal of Interventional Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2096360223000492/pdfft?md5=9c25c94f22db8436f08c43d107d93391&pid=1-s2.0-S2096360223000492-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135761082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}